MiR-214 promotes tumorigenesis by targeting lactotransferrin in nasopharyngeal carcinoma

Tumor Biology

Volumn 34, Issue 3, 2013, Pages 1793-1800

  Deng, Min ^a,b   Ye, Qiurong ^a   Qin, Zailong ^a   Zheng, Ying ^a   He, Wei ^a   Tang, Hailin ^a   Zhou, Yanhong ^a   Xiong, Wei ^a   Zhou, Ming ^a   Li, Xiaoling ^a   Yan, Qun ^a   Ma, Jian ^a   Li, Guiyuan ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

AKT; LTF; miR 214; Nasopharyngeal carcinoma

Indexed keywords

LACTOFERRIN; MESSENGER RNA; MICRORNA; MICRORNA 185; MICRORNA 214; MICRORNA 449A; MICRORNA 449B; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER MODEL; CARCINOGENESIS; CARCINOMA CELL; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE OVEREXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LUNG METASTASIS; MALE; MOUSE; NASOPHARYNX CARCINOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; TUMOR INVASION; TUMOR XENOGRAFT; UPREGULATION;

EID: 84878701179     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-0718-y     Document Type: Article

References (28)

1. Legrand D. Lactoferrin, a key molecule in immune and inflammatory processes. Biochem Cell Biol. 2012;90(3):252-68.
2. Legrand D, Pierce A, Elass E, Carpentier M, Mariller C, et al. Lactoferrin structure and functions. Adv Exp Med Biol. 2008;606:163-94.
3. Alexander DB, Iigo M, Yamauchi K, Suzui M, Tsuda H. Lactoferrin: an alternative view of its role in human biological fluids. Biochem Cell Biol. 2012;90(3):279-306.
4. Bezault J, Bhimani R, Wiprovnick J, Furmanski P. Human lactoferrin inhibits growth of solid tumors and development of experimental metastases in mice. Cancer Res. 1994;54(9):2310-2.
5. Li WY, Li QW, Han ZS, Jiang ZL, Yang H, et al. Growth suppression effects of recombinant adenovirus expressing human lactoferrin on cervical cancer in vitro and in vivo. Cancer Biother Radiopharm. 2011;26(4):477-83.
6. Matsuda Y, Saoo K, Hosokawa K, Yamakawa K, Yokohira M, et al. Post-initiation chemopreventive effects of dietary bovine lactoferrin on 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced lung tumorigenesis in female A/J mice. Cancer Lett. 2007;246(1-2):41-6.
7. Sekine K, Watanabe E, Nakamura J, Takasuka N, Kim DJ, et al. Inhibition of azoxymethane-initiated colon tumor by bovine lactoferrin administration in F344 rats. Jpn J Cancer Res. 1997;88(6):523-6.
8. Tsuda H, Sekine K, Nakamura J, Ushida Y, Kuhara T, et al. Inhibition of azoxymethane initiated colon tumor and aberrant crypt foci development by bovine lactoferrin administration in F344 rats. Adv Exp Med Biol. 1998;443:273-84.
9. Varadhachary A, Wolf JS, Petrak K, O'Malley Jr BW, Spadaro M, et al. Oral lactoferrin inhibits growth of established tumors and potentiates conventional chemotherapy. Int J Cancer. 2004;111(3):398-403.
10. Tuccari G, Barresi G. Lactoferrin in human tumours: immunohistochemical investigations during more than 25 years. Biometals. 2011;24(5):775-84.
11. Zhou Y, Zeng Z, Zhang W, Xiong W, Wu M, et al. Lactotransferrin: a candidate tumor suppressor-deficient expression in human nasopharyngeal carcinoma and inhibition of NPC cell proliferation by modulating the mitogen-activated protein kinase pathway. Int J Cancer. 2008;123(9):2065-72.
12. Deng M, Zhang W, Tang H, Ye Q, Liao Q, et al. Lactotransferrin acts as a tumor suppressor in nasopharyngeal carcinoma by repressing AKT through multiple mechanisms. Oncogene. 2012. doi: 10.1038/onc.2012.434. Epub ahead of print.
13. Deng L, Jing N, Tan G, Zhou M, Zhan F, et al. A common region of allelic loss on chromosome region 3p25.3-26.3 in nasopharyngeal carcinoma. Genes Chromosomes Cancer. 1998;23(1):21-5.
14. Xiong W, Zeng ZY, Xia JH, Xia K, Shen SR, et al. A susceptibility locus at chromosome 3p21 linked to familial nasopharyngeal carcinoma. Cancer Res. 2004;64(6):1972-4.
15. Yi HM, Li H, Peng D, Zhang HJ, Wang L, et al. Genetic and epigenetic alterations of LTF at 3p21.3 in nasopharyngeal carcinoma. Oncol Res. 2006;16(6):261-72.
16. Zhang H, Feng X, Liu W, Jiang X, Shan W, et al. Underlying mechanisms for LTF inactivation and its functional analysis in nasopharyngeal carcinoma cell lines. J Cell Biochem. 2011;112(7):1832-43.
17. Bushati N, Cohen SM. microRNA functions. Annu Rev Cell Dev Biol. 2007;23:175-205.
18. Mao YP, Li WF, Chen L, Sun Y, Liu LZ, et al. A clinical verification of the Chinese 2008 staging system for nasopharyngeal carcinoma. Ai Zheng. 2009;28(10):1022-8.
19. Sun Y, Ma J. Comment for the Chinese 2008 staging system for nasopharyngeal carcinoma. Ai Zheng. 2009;28(10):1016-21.
20. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001;29(9):e45.
21. Liao Y, Du X, Lonnerdal B. miR-214 regulates lactoferrin expression and pro-apoptotic function in mammary epithelial cells. J Nutr. 2010;140(9):1552-6.
22. Teng C, Gladwell W, Raphiou I, Liu E. Methylation and expression of the lactoferrin gene in human tissues and cancer cells. Biometals. 2004;17(3):317-23.
23. Lu M, Zhang Q, Deng M, Miao J, Guo Y, et al. An analysis of human microRNA and disease associations. PLoS One. 2008;3(10):e3420.
24. Yang H, Kong W, He L, Zhao JJ, O'Donnell JD, Wang J, et al. MicroRNA expression profiling in human ovarian cancer: Mir-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res. 2008;68:425-33.
25. Kanaan Z, Rai SN, Eichenberger MR, Barnes C, Dworkin AM, et al. Differential microRNA expression tracks neoplastic progression in inflammatory bowel disease-associated colorectal cancer. Hum Mutat. 2012;33(3):551-60.
26. Vergoulis T, Vlachos IS, Alexiou P, Georgakilas G, Maragkakis M, et al. TarBase 6.0: capturing the exponential growth of miRNA targets with experimental support. Nucleic Acids Res. 2012;40:D222-9. Database issue.
27. Penna E, Orso F, Cimino D, Tenaglia E, Lembo A, et al. microRNA-214 contributes to melanoma tumour progression through suppression of TFAP2C. EMBO J. 2011;30(10):1990-2007.
28. Yang Z, Chen S, Luan X, Li Y, Liu M, et al. MicroRNA-214 is aberrantly expressed in cervical cancers and inhibits the growth of HeLa cells. IUBMB Life. 2009;61(11):1075-82.